MedTrace Logo

A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.

NCT00379067 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 882

Last updated 2014-10-10

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Tamsulosin OCAS

Adrenoceptor antagonist

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    collaborator INDUSTRY

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Medical Affairs Europe, Astellas Pharma Europe Limited, Lovett House, Lovett Road, Staines Middlesex TW 18 3AZ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-11-30
Completion
2006-11-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00379067 on ClinicalTrials.gov